MedPath

International Vaccine Institute

International Vaccine Institute logo
🇰🇷South Korea
Ownership
Private
Established
1997-01-01
Employees
51
Market Cap
-
Website
http://www.ivi.int

Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

Phase 3
Not yet recruiting
Conditions
COVID-19 Disease
Interventions
Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
Biological: influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
First Posted Date
2021-07-30
Last Posted Date
2021-08-16
Lead Sponsor
International Vaccine Institute
Target Recruit Count
8825
Registration Number
NCT04984408

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana

Phase 4
Recruiting
Conditions
Typhoid Fever
Interventions
Biological: MCV-A vaccine
Biological: Vi-TT
First Posted Date
2021-04-21
Last Posted Date
2024-03-08
Lead Sponsor
International Vaccine Institute
Target Recruit Count
23000
Registration Number
NCT04852185
Locations
🇬🇭

Kwame Nkrumah University of Science and Technology, Kumasi, Ashanti, Ghana

Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

Phase 3
Completed
Conditions
Cholera
Interventions
Biological: Oral Cholera Vaccine Simplified (OCV-S)
Biological: Shanchol™
First Posted Date
2021-02-18
Last Posted Date
2023-06-22
Lead Sponsor
International Vaccine Institute
Target Recruit Count
2530
Registration Number
NCT04760236
Locations
🇳🇵

Nepalgunj medical college, Banke, City- Nepalgunj, Nepal

🇳🇵

B.P.Koirala Institute of Health Sciences, Rautahat, Dharan, Nepal

🇳🇵

Dhulikhel Hospital, Kavre, Dhulikhel, Nepal

and more 1 locations

Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia

Phase 2
Active, not recruiting
Conditions
Chikungunya
Interventions
Drug: BBV87 Chikungunya vaccine
Drug: Normal Saline
First Posted Date
2020-09-28
Last Posted Date
2023-04-19
Lead Sponsor
International Vaccine Institute
Target Recruit Count
3210
Registration Number
NCT04566484
Locations
🇨🇴

Clínica de la Costa, Barranquilla, Atlantico, Colombia

🇬🇹

Centro de Estudios Clínicos Salud Avanzada. (CECLISA), Guatemala city, Guatemala

🇨🇴

Centro de Atención en Investigación Médica (CAIMED)., Yopal, Casanare, Colombia

and more 4 locations

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Phase 1
Completed
Conditions
Coronavirus Infection
SARS-CoV 2
Interventions
Biological: INO-4800
Device: CELLECTRA® 2000
Other: Saline-sodium citrate (SSC) buffer
First Posted Date
2020-06-25
Last Posted Date
2022-07-18
Lead Sponsor
International Vaccine Institute
Target Recruit Count
79
Registration Number
NCT04447781
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

Phase 3
Completed
Conditions
Typhoid
Interventions
Biological: Vi-DT (Multi-dose formulation)
Biological: Vi-DT (Single dose formulation)
Biological: Control Vaccine
First Posted Date
2019-12-18
Last Posted Date
2021-08-27
Lead Sponsor
International Vaccine Institute
Target Recruit Count
1800
Registration Number
NCT04204096
Locations
🇵🇭

Putatan Research Center, Muntinlupa, Metro Manila, Philippines

🇵🇭

Lingga Health Research Center, Calamba, Laguna, Philippines

🇵🇭

University of the Philippines Manila-National Institutes of Health, Manila, Philippines

and more 1 locations

Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine

Phase 3
Conditions
Typhoid
Interventions
Biological: Test Vaccine Vi-DT Typhoid conjugate
Biological: Control Vaccine Typbar TCV®
First Posted Date
2019-05-01
Last Posted Date
2020-04-22
Lead Sponsor
International Vaccine Institute
Target Recruit Count
1800
Registration Number
NCT03933098
Locations
🇳🇵

Nepalgunj medical college, Banke, City- Nepalgunj, Nepal

🇳🇵

Dhulikhel Hospital, Kavre, Dhulikhel, Nepal

🇳🇵

Kanti Children's Hospital, Kathmandu, Sukedhara, Nepal

and more 1 locations

Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand

Not Applicable
Conditions
Healthy
Interventions
Biological: Bivalent HPV vaccine CERVARIX®
First Posted Date
2018-11-20
Last Posted Date
2020-04-22
Lead Sponsor
International Vaccine Institute
Target Recruit Count
18000
Registration Number
NCT03747770
Locations
🇹🇭

Ministry of Public Health, Bangkok, Chang Wat Nonthaburi, Thailand

Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine

Phase 2
Completed
Conditions
Typhoid
Interventions
Biological: Vi-DT
Biological: FluQuadri™
Other: 0.9% sodium chloride isotonic solution
First Posted Date
2018-05-17
Last Posted Date
2021-08-27
Lead Sponsor
International Vaccine Institute
Target Recruit Count
285
Registration Number
NCT03527355
Locations
🇵🇭

Research Institute for Tropical Medicine(RITM), Alabang, Muntinlupa City, Philippines

Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Phase 1
Completed
Conditions
Typhoid
Interventions
Biological: Vi-DT
Biological: Typhim Vi®
Biological: VAXIGRIP®
First Posted Date
2016-01-01
Last Posted Date
2020-04-28
Lead Sponsor
International Vaccine Institute
Target Recruit Count
144
Registration Number
NCT02645032
© Copyright 2025. All Rights Reserved by MedPath